Loading clinical trials...
Loading clinical trials...
A Phase 1, Pharmacokinetic Comparability Study of Intravenous and Subcutaneous Administration of Risankizumab in Healthy Subjects
Conditions
Interventions
Risankizumab
Risankizumab
+1 more
Locations
8
United States
Anaheim Clinical Trials LLC /ID# 222821
Anaheim, California, United States
Altasciences Clinical Los Angeles, Inc /ID# 222238
Cypress, California, United States
Clinical Pharmacology of Miami /ID# 225392
Miami, Florida, United States
PPD Clinical Research Unit /ID# 222362
Orlando, Florida, United States
Acpru /Id# 222349
Grayslake, Illinois, United States
PPD Clinical Research Unit -Las Vegas /ID# 222363
Las Vegas, Nevada, United States
Start Date
September 1, 2020
Primary Completion Date
July 6, 2021
Completion Date
July 6, 2021
Last Updated
March 10, 2022
NCT07310264
NCT06342713
NCT07472361
NCT06649110
NCT06823947
NCT07240675
Lead Sponsor
AbbVie
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions